Rodman and Renshaw Initiates Coverage on Biosante Pharmaceuticals (BPAX) with an Outperform
More News related to BPAX
- BioSante Pharmaceuticals Appoints Jeffrey W. Winkelman, Ph.D., J.D., Vice President, Oncology Programs
- BioSante Pharmaceuticals, Inc. To Present At BIO CEO & Investor Conference
- BioSante Pharmaceuticals, Inc. To Present At OneMedForum and Biotech Showcase Conferences
- BioSante Pharma (BPAX) Monetizes Portion of Elestrin Royalty Stream for $1M
- Rodman and Renshaw Initiates Coverage on Biosante Pharmaceuticals (BPAX) with an Outperform
More News related to New Coverage
- Janney Montgomery Scott Initiates Coverage on Papa John's International (PZZA) with a Neutral
- Feltl & Co. Initiates Coverage on ActivIdentity (ACTI) with a Buy
- Oscar Gruss Initiates Coverage Airgas (ARG) with a Buy
- Sidoti & Co Initiates Coverage on Solutia (SOA) with a Buy
- RBC Capital Initiates Coverage on Questar (STR) with a Sector Perform
Rodman and Renshaw initiates coverage on Biosante Pharmaceuticals (Nasdaq: BPAX) with an Outperform. Price target $4.
To see more analyst ratings on BPAX Click Here.
Biosante Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism.
Related Categories
New CoverageStocks Mentioned
+0.06Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
